Skip to content

Clinical Study on the Efficacy and Safety of Applying Skinceuticals CE Ferulicin Following Non-ablative Fractional Laser in Promoting Repair

Clinical Study on the Efficacy and Safety of Applying Skinceuticals CE Ferulicin Following Non-ablative Fractional Laser in Promoting Repair

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069246
Enrollment
Unknown
Registered
2023-03-10
Start date
2023-03-10
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Photo-aging

Interventions

Experimental group:On the test side, immediately after laser surgery, Skinceuticals CE Ferulicin and Skinceuticals Phyto Corrective were successively used, while on the control side, only Skinceutical

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this experiment, have signed informed consent, can use test products as required and complete follow-up; 2. Chinese subjects aged between 18 and 60 years; 3. The face has the need of anti-aging and pore treatment, and fiber dot matrix laser is planned to be performed; 4. Be willing to take care of sun protection throughout the study period and not be exposed to direct sunlight.

Exclusion criteria

Exclusion criteria: 1. Pregnant, expectant and lactating women or less than half a year after delivery; 2. Patients with serious systemic diseases in the past, including tumor, blood clotting tendency and coagulation dysfunction, or complicated liver and cardiovascular diseases, as well as previous history of thrombosis and cerebral ischemia; 3. Patients with facial inflammatory skin diseases, such as acne, rosette acne, dermatitis, chloasma, vitiligo and other pigmented skin diseases, patients with large area seborrheic keratosis; 4. Allergic to the test product; 5. Patients who are currently participating in other clinical studies or have participated in other clinical studies within 3 months; 6. The researchers deemed it unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Skin photography;

Secondary

MeasureTime frame
Skin physiological indicators (Skin water content, transepidermal water loss, skin color);Investigator subjective assessment;Subject pain score;Safety assessments;Product usage sensation and satisfaction assessment;

Countries

China

Contacts

Public ContactWu Yan

Peking University First Hospital

15810700716@126.com+86 139 1097 8643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026